Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int J Surg Oncol. 2012;2012:613980. doi: 10.1155/2012/613980. Epub 2012 Aug 5.

The role of secondary surgery in recurrent ovarian cancer.

Author information

  • 1Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.

Abstract

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

PMID:
22919475
[PubMed]
PMCID:
PMC3420128
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk